TABLE III.
Characteristics of reported cases of anaphylaxis among persons without a history of hypersensitivity by age group, 1990–2016
| <4 y (%), n = 74 |
4–10 y (%), n = 105 |
11–18 y (%), n = 35 |
19–49 y (%), n = 84 |
≥50+ y (%), n = 43 |
Total (%), n = 341 |
|
|---|---|---|---|---|---|---|
| Seriousness of report | ||||||
| Death | 1 (1) | 0 (0) | 0 (0) | 1 (1) | 2 (5) | 4 (1) |
| Serious, nondeath* | 64 (86) | 87 (83) | 29 (83) | 63 (75) | 32 (74) | 275 (81) |
| Nonserious | 9 (12) | 18 (17) | 6 (17) | 20 (24) | 9 (21) | 62 (18) |
| Sex of reported patient | ||||||
| Male | 44 (59) | 72 (69) | 15 (43) | 20 (24) | 15 (35) | 166 (49) |
| Female | 29 (39) | 33 (31) | 20 (57) | 64 (76) | 28 (65) | 174 (51) |
| Unreported | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) |
| Treatment† | ||||||
| Antihistamines | 55 (74) | 79 (75) | 20 (57) | 58 (69) | 30 (70) | 242 (71) |
| Epinephrine | 42 (57) | 79 (75) | 25 (71) | 45 (54) | 25 (58) | 216 (63) |
| Steroids | 43 (58) | 56 (53) | 21 (60) | 56 (67) | 29 (67) | 205 (60) |
| No treatment specified | 10 (14) | 7 (7) | 3 (9) | 12 (14) | 4 (9) | 36 (11) |
| Time to onset | ||||||
| <30 min | 40 (54) | 65 (62) | 15 (43) | 31 (37) | 12 (28) | 163 (48) |
| 30–119 min | 15 (20) | 21 (20) | 6 (17) | 20 (24) | 5 (12) | 67 (20) |
| 2–4 h | 7 (9) | 2 (2) | 5 (14) | 8 (10) | 8 (19) | 30 (9) |
| 4–8 h | 5 (7) | 2 (2) | 2 (6) | 7 (8) | 6 (14) | 22 (6) |
| 8–24 h | 4 (5) | 0 (0) | 3 (9) | 6 (7) | 8 (19) | 21 (6) |
| Not reported | 3 (4) | 15 (14) | 4 (11) | 12 (14) | 4 (9) | 38 (11) |
*
Reports in which the patient was hospitalized, had prolongation of hospitalization, had permanent disability, or experienced a life-threatening condition.
†
Some reports described patients who received more than 1 type of treatment.